Related references
Note: Only part of the references are listed.Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis
Eli Muchtar et al.
LEUKEMIA (2020)
High-dose melphalan and stem cell transplantation in systemic AL amyloidosis in the era of novel anti-plasma cell therapy: a comprehensive review
Cindy Varga et al.
BONE MARROW TRANSPLANTATION (2019)
Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial
Monique C. Minnema et al.
HAEMATOLOGICA (2019)
Combination of bortezomib in the induction, conditioning and consolidation with autologous hematopoietic stem cell transplantation in patients with immunoglobulin light chain amyloidosis
Xianghua Huang et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Bone marrow plasma cell infiltration in light chain amyloidosis: impact on organ involvement and outcome
Natalia Tovar et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2018)
Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation
Aimaz Afrough et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Turn off the Tap! The Need for Induction Therapy for AL Amyloidosis Before Transplant
Joseph Mikhael
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Systemic immunoglobulin light chain amyloidosis
Giampaolo Merlini et al.
NATURE REVIEWS DISEASE PRIMERS (2018)
Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis
H. Landau et al.
LEUKEMIA (2017)
AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis
Tobias Dittrich et al.
BLOOD (2017)
Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome
Paolo Milani et al.
BLOOD (2017)
Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death
Eli Muchtar et al.
BLOOD (2017)
Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation
Yi L. Hwa et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Bortezomib with dexamethasone as first-line treatment for AL amyloidosis with renal involvement
Xianghua Huang et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2016)
The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell Transplantation
Christopher Dittus et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Immunomodulatory drugs in AL amyloidosis
T. Jelinek et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies
Efstathios Kastritis et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Annyloidosis: Results of a Prospective Clinical Trial
Vaishali Sanchorawala et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study
Anita D'Souza et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement
Angela Dispenzieri et al.
MAYO CLINIC PROCEEDINGS (2015)
A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis
Giovanni Palladini et al.
BLOOD (2014)
Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial
Xianghua Huang et al.
BMC MEDICINE (2014)
Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens
Shameem Mahmood et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Induction Bortezomib in AL Amyloidosis Followed By High Dose Melphalan and Autologous Stem Cell Transplantation: A Single Institution Retrospective Study
Emma C. Scott et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2014)
High Dose Melphalan and Autologous Peripheral Blood Stem Cell Transplantation in AL Amyloidosis
Vaishali Sanchorawala
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2014)
Coexistent Multiple Myeloma or Increased Bone Marrow Plasma Cells Define Equally High-Risk Populations in Patients With Immunoglobulin Light Chain Amyloidosis
Taxiarchis V. Kourelis et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis
H. Landau et al.
LEUKEMIA (2013)
New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes
Giovanni Palladini et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements
Shaji Kumar et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis
R. L. Comenzo et al.
LEUKEMIA (2012)
Transplantation vs. conventional-dose therapy for amyloidosis
Giovanni Palladini et al.
CURRENT OPINION IN ONCOLOGY (2011)
Amyloidosis: Pathogenesis and New Therapeutic Options
Giampaolo Merlini et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Bortezomib With or Without Dexamethasone in Primary Systemic (Light Chain) Amyloidosis
Efstathios Kastritis et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis
MA Gertz et al.
AMERICAN JOURNAL OF HEMATOLOGY (2005)
High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial
V Sanchorawala et al.
BONE MARROW TRANSPLANTATION (2004)
Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis
A Dispenzieri et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study
JB Perz et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival
A Dispenzieri et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Share Paper
